Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H ( (HK:2315) ) has issued an announcement.
Biocytogen Pharmaceuticals announced a significant improvement in its financial performance for 2024, with an expected revenue increase of approximately 35.2% to 38.0% compared to 2023, and a potential net profit of RMB20.0 million to RMB40.0 million, contrasting with a loss in the previous year. The improved results are attributed to expanding overseas recognition in the antibody discovery business, rapid growth in the gene editing animal model segment, and strategic adjustments leading to reduced R&D expenses and enhanced operational efficiency.
More about Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. is a Chinese company operating in the biotechnology industry, primarily focused on antibody discovery and gene editing animal model services. The company targets overseas markets and emphasizes high gross profit margins in its operations.
YTD Price Performance: -7.29%
Average Trading Volume: 152,457
Technical Sentiment Consensus Rating: Hold
Current Market Cap: HK$3.14B
For an in-depth examination of 2315 stock, go to TipRanks’ Stock Analysis page.
